查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1540794

2024-2032 年药物警戒市场报告（按服务提供者、产品生命週期、类型、流程、治疗领域、最终用途和地区划分）

Pharmacovigilance Market Report by Service Provider, Product Life Cycle, Type, Process Flow, Therapeutic Area, End Use, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年全球药物警戒市场规模达79亿美元。药物不良反应（ADR）的日益普遍，加上政府机构推出有利政策以提高人们对正确使用药物的认识并进行临床试验，主要刺激了药物警戒市场的成长。

全球药物警戒市场分析：

主要市场驱动因素：各种生活方式疾病（包括心臟病、高血压、糖尿病等）发病率的上升正在增加全球药物的使用。因此，对药物警戒（PV）的需求不断增加，以检测以前未知的不良反应，识别频率或严重程度的变化，评估药物的风险和益处以确定所需的行动等。的机会药物警戒市场前景。

主要市场趋势：药物警戒市场的主要趋势之一包括开发先进平台以确保自动报告药物不良反应 (ADR)。此外，由于竞争环境，主要参与者也专注于加强製造业务和简化研发活动。除此之外，临床试验数量的增加预计将在预测期内推动药物警戒市场的发展。

竞争格局：一些着名的药物警戒市场主要参与者包括Accenture plc、ArisGlobal LLC、BioClinica Inc. (Cinven Partners LLP)、Capgemini、Cognizant、International Business Machines Corporation、ICON plc.、IQVIA Inc.、ITClinical、Parexel International Corporation 、及 Wipro Limited 等。

挑战与机会：根据药物警戒市场分析，一些挑战包括政府机构严格的监管要求、管理和从大量资料中获取有意义的见解的复杂性不断增加，以及平衡全面药物安全监测的需求日益增加控製成本的压力正在阻碍全球药物警戒产业的成长。然而，促进策略合作以确保药品安全和维护公众健康预计将在未来几年推动药物警戒市场份额的成长。

全球药物警戒市场趋势：

技术不断进步的发展

机器学习 (ML)、自然语言处理 (NLP)、人工智慧 (AI)、巨量资料分析等新技术的日益整合正在增强药物警戒流程。与此一致，这些技术正在获得广泛的关注，因为它们有助于识别不良事件、风险评估、实现有效的讯号检测等，预计这将在预测期内推动市场成长。例如，赛诺菲和德勤合作开发了ConvergeHEALTH Safety，这是下一代人工智慧(AI) 软体即服务不良事件案例受理平台，该平台改变了药物警戒(PV) 流程并解决了行业中一些最紧迫的操作安全问题。为此，ArisGlobal 推出了 USFDA 不良事件报告系统 (FAERS II)，这是一个由 LifeSphere MultiVigilance 提供支援的电子安全报告平台，推动了市场成长。此外，Saama Technologies Inc. 开发了新的製药主动安全分析 (ASAP) 产品。 ASAP 是首批经过验证的药物警戒解决方案之一，利用 TreeScan 方法和美国食品药物管理局 (FDA) 的哨兵通用资料模型来检测安全讯号。

政府机关实施严格的法规

全球各地的政府当局正在临床试验中实施严格的规则，并提高人们对正确使用药物的认识，这正在刺激药物警戒服务的使用。例如，根据《药物安全与监管前沿》发表的一项研究，上市后药物评估的重要性对于描述现实环境中的药物安全状况非常重要。此类研究进一步提高了药物警戒的重要性，从而刺激了市场成长。此外，由于存在 N-亚硝基喹那普利和亚硝胺药物相关杂质 (NDSRI)，Aurobindo Pharma USA 重新配製了喹那普利和氢氯噻嗪片 USP 20mg/12.5mg。因此，监管机构对医疗资讯日益增长的需求预计将推动预测期内的市场成长。

製药公司越来越多地采用药物警戒服务

药物警戒服务因其优势（例如在更短的时间内获得更好的结果以及提高内部资源灵活性）而被全球主要製药公司广泛采用。例如，根据疫苗不良事件通报系统的数据，在註射了 4,041,396 剂 Moderna COVID-19 疫苗后，发现了 10 例过敏反应病例（每百万剂中有 2.5 例）。因此，对药物警戒服务不断增长的需求也刺激了市场的成长。除此之外，主要产业参与者也正在进行策略合作，这将在预测期内继续推动药物警戒市场的发展。例如，IQVIA 与 NRx Pharmaceuticals 达成策略合作，提供医疗资讯和药物警戒服务，为潜在的监管行动做好准备。

高级临床试验阶段的数量不断增加

为了提高临床试验的功效，主要参与者正在开发先进的临床试验，这正在刺激全球药物警戒市场。例如，Cognizant 与 Medable Inc. 建立合作关係，共同提供基于 Medable 的软体即服务平台的临床研究解决方案，用于分散式临床试验。据此，根据药物警戒市场概况，Viedoc 与 LINK Medical 建立了 Viedoc 建立的合作关係。此次合作旨在提高 LINK Medical 及其客户的试验效率。这种伙伴关係允许交流需求、经验、想法等，并测试新功能。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球药物警戒市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：按服务提供者

  • 内部
    • 市场趋势
    • 市场预测
  • 合约外包
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：依产品生命週期

  • 临床前
    • 市场趋势
    • 市场预测
  • 第一阶段
    • 市场趋势
    • 市场预测
  • 第二阶段
    • 市场趋势
    • 市场预测
  • 第三阶段
    • 市场趋势
    • 市场预测
  • 第四阶段
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：按类型

  • 自发性报告
    • 市场趋势
    • 市场预测
  • 强化 ADR 报告
    • 市场趋势
    • 市场预测
  • 针对性的自发性报告
    • 市场趋势
    • 市场预测
  • 群组事件监控
    • 市场趋势
    • 市场预测
  • 电子病历采矿
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：依製程流程

  • 案例资料管理
    • 市场趋势
    • 主要类型
      • 案例记录
      • 案例数据分析
      • 医学审查和报告
    • 市场预测
  • 讯号检测
    • 市场趋势
    • 主要类型
      • 不良事件记录
      • 不良事件分析
      • 不良事件审查和报告
    • 市场预测
  • 风险管理系统
    • 市场趋势
    • 主要类型
      • 风险评估体系
      • 风险缓释系统
    • 市场预测

第 10 章：市场区隔：依治疗领域

  • 肿瘤学
    • 市场趋势
    • 市场预测
  • 神经病学
    • 市场趋势
    • 市场预测
  • 心臟病学
    • 市场趋势
    • 市场预测
  • 呼吸系统
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 11 章：市场区隔：最终用途别

  • 製药公司
    • 市场趋势
    • 市场预测
  • 生技公司
    • 市场趋势
    • 市场预测
  • 医疗器材公司
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 12 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 13 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 14 章：价值链分析

第 15 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 16 章：价格分析

第17章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Accenture plc
    • ArisGlobal LLC
    • BioClinica Inc. (Cinven Partners LLP)
    • Capgemini
    • Cognizant
    • International Business Machines Corporation
    • ICON plc.
    • IQVIA Inc.
    • ITClinical
    • Parexel International Corporation
    • Wipro Limited
Product Code: SR112024A3609

The global pharmacovigilance market size reached US$ 7.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 15.9 Billion by 2032, exhibiting a growth rate (CAGR) of 7.8% during 2024-2032. The increasing prevalence of adverse drug reactions (ADRs), coupled with the launch of favorable policies by government bodies to generate awareness about the proper usage of medicines and conduct clinical trials, is primarily stimulating the pharmacovigilance market growth.

Global Pharmacovigilance Market Analysis:

Major Market Drivers: The elevating incidences of various lifestyle diseases, including cardiac disorders, hypertension, diabetes, etc., are augmenting the usage of drugs across the globe. Consequently, there is an elevating need for pharmacovigilance (PV) to detect previously unknown adverse effects, recognize changes in the frequency or severity, assess the risks and benefits of drugs to determine required actions, etc. This, in turn, is providing significant opportunities in the pharmacovigilance market outlook.

Key Market Trends: One of the key pharmacovigilance market trends includes the development of advanced platforms to ensure automated adverse drug reactions (ADR) reporting. Furthermore, key players are also focusing on enhancing manufacturing operations and streamlining R&D activities, owing to the competitive environment. Besides this, the rising number of clinical trials is expected to fuel the pharmacovigilance market in the forecasted period.

Competitive Landscape: Some of the prominent pharmacovigilance market key players are Accenture plc, ArisGlobal LLC, BioClinica Inc. (Cinven Partners LLP), Capgemini, Cognizant, International Business Machines Corporation, ICON plc., IQVIA Inc., ITClinical, Parexel International Corporation, and Wipro Limited, among many others.

Challenges and Opportunities: According to the pharmacovigilance market analysis, some of the challenges, including stringent regulatory requirements by government bodies, the rising complexities in managing and deriving meaningful insights from a vast amount of data, and the increasing need for balancing comprehensive drug safety monitoring with the pressure to control costs, are hindering the growth of the pharmacovigilance industry across the globe. However, fostering strategic collaborations to ensure the safety of drugs and safeguard public health is expected to propel the pharmacovigilance market share in the coming years.

Global Pharmacovigilance Market Trends:

The Development of Continuous Technological Advancements

The increasing integration of novel technologies, such as machine learning (ML), natural language processing (NLP), artificial intelligence (AI), big data analytics, etc., is enhancing the pharmacovigilance processes. In line with this, these technologies are gaining extensive traction, as they help in identifying adverse events, risk assessments, enabling efficient signal detection, etc., which is expected to fuel the market growth over the forecasted period. For instance, Sanofi and Deloitte collaborated on ConvergeHEALTH Safety, a next-generation artificial intelligence (AI) software-as-a-service adverse events case intake platform that transformed pharmacovigilance (PV) processes and addressed some of the industry's most pressing operational safety issues. In line with this, ArisGlobal introduced the go-live of the USFDA Adverse Event Reporting System (FAERS II), an electronic safety reporting platform powered by LifeSphere MultiVigilance, which propelled the market growth. Furthermore, Saama Technologies Inc. developed the new Active Safety Analytics for Pharma (ASAP) products. ASAP is one of the first validated pharmacovigilance solutions to leverage the TreeScan methodology and the United States Food and Drug Administration's (FDA) Sentinel Common Data Model for detecting safety signals.

Stringent Regulations Implemented by Government Bodies

Government authorities across the globe are implementing strict rules in clinical trials and generating awareness regarding the proper utilization of medicines, which is stimulating the usage of pharmacovigilance services. For example, according to a study published in Frontiers in Drug Safety and Regulation, the significance of post-marketing medication evaluation is important for characterizing drug safety profiles in real-world settings. Such studies are further increasing the importance of pharmacovigilance, thereby stimulating the market growth. Moreover, Aurobindo Pharma USA reformulated Quinapril and Hydrochlorothiazide Tablets USP 20mg/12.5mg, owing to the presence of N-Nitroso-Quinapril and Nitrosamine Drug Substance Related Impurity (NDSRI). Consequently, the inflating need for medical information among regulatory authorities is expected to fuel the market growth over the forecasted period.

The Rising Adoption of Pharmacovigilance Services by Pharmaceutical Companies

Pharmacovigilance services are extensively adopted by key pharmaceutical companies across the globe, owing to benefits, such as better outcomes over shorter periods and increasing internal resource flexibility. For example, according to the Vaccine Adverse Event Reporting System, 10 cases of anaphylaxis were detected after the administration of a reported 4,041,396 first doses of the Moderna COVID-19 vaccine (2.5 cases per million doses). Consequently, the growing need for pharmacovigilance services is also stimulating the market growth. In addition to this, key industry players are also entering into strategic collaborations, which will continue to propel the pharmacovigilance market over the forecasted period. For example, IQVIA entered into a strategic collaboration with NRx Pharmaceuticals to offer medical information and pharmacovigilance services in preparation for potential regulatory actions.

The Growing Number of Advanced Clinical Trial Phases

To enhance the efficacy of clinical trials, major prominent players are developing advanced clinical trials, which are stimulating the global market for pharmacovigilance. For example, Cognizant entered into a partnership with Medable Inc. to jointly deliver clinical research solutions based on Medable's software-as-a-service platform for decentralized clinical trials. In line with this, according to the pharmacovigilance market overview, Viedoc and LINK Medical entered into a partnership established by Viedoc. The collaboration was designed to enhance trial efficiency for LINK Medical and its clients. The partnership allowed for the exchange of needs, experience, ideas, etc., and the testing of new features.

Pharmacovigilance Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global pharmacovigilance market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on service provider, product life cycle, type, process flow, therapeutic area, and end use.

Breakup by Service Provider:

In-house

Contract Outsourcing

The report has provided a detailed breakup and analysis of the market based on the service provider. This includes in-house and contract outsourcing.

Breakup by Product Life Cycle:

Pre-clinical

Phase I

Phase II

Phase III

Phase IV

A detailed breakup and analysis of the market based on the product life cycle has also been provided in the report. This includes pre-clinical, Phase I, Phase II, Phase III, and Phase IV.

Breakup by Type:

Spontaneous Reporting

Intensified ADR Reporting

Targeted Spontaneous Reporting

Cohort Event Monitoring

EHR Mining

The report has provided a detailed breakup and analysis of the market based on the type. This includes spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, cohort event monitoring, and EHR Mining.

Breakup by Process Flow:

Case Data Management

Case Logging

Case Data Analysis

Medical Reviewing and Reporting

Signal Detection

Adverse Event Logging

Adverse Event Analysis

Adverse Event Review and Reporting

Risk Management System

Risk Evaluation System

Risk Mitigation System

The report has provided a detailed breakup and analysis of the market based on the process flow. This includes case data management (case logging, case data analysis, medical reviewing and reporting), signal detection (adverse event logging, adverse event analysis, and adverse event review and reporting, and risk management system (risk evaluation system and risk mitigation system).

Breakup by Therapeutic Area:

Oncology

Neurology

Cardiology

Respiratory Systems

Others

The report has provided a detailed breakup and analysis of the market based on the therapeutic area. This includes oncology, neurology, cardiology, respiratory systems, and others.

Breakup by End Use:

Pharmaceuticals Companies

Biotechnology Companies

Medical Device Companies

Others

The report has provided a detailed breakup and analysis of the market based on the end-use. This includes pharmaceuticals companies, biotechnology companies, medical device companies, and others.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

Competitive Landscape:

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the pharmacovigilance top companies are listed below:

Accenture plc

ArisGlobal LLC

BioClinica Inc. (Cinven Partners LLP)

Capgemini

Cognizant

International Business Machines Corporation

ICON plc.

IQVIA Inc.

ITClinical

Parexel International Corporation

Wipro Limited

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Global Pharmacovigilance Market News:

March 2024: The American Society of Pharmacovigilance (ASP), along with several partners, is focused on advancing drug safety via minimizing ADEs, the fourth leading cause of death in the United States.

February 2024: The Indian Pharmacopoeia Commission (IPC) released the Draft Pharmacovigilance Guidance Document for pharmaceutical products for its latest Version 2.0. The Commission also offered suggestions from Marketing Authorization Holders (MAHs) on the draft document.

February 2024: The US Food and Drug Administration (FDA) Office of Surveillance and Epidemiology (OSE) launched the standardization of Risk Evaluation and Mitigation Strategies (REMS) data to facilitate its use.

Key Questions Answered in This Report:

  • How has the global pharmacovigilance market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global pharmacovigilance market?
  • What are the key regional markets?
  • What is the breakup of the market based on the service provider?
  • What is the breakup of the market based on the product life cycle?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the process flow?
  • What is the breakup of the market based on the therapeutic area?
  • What is the breakup of the market based on the end use?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global pharmacovigilance market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pharmacovigilance Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Service Provider

  • 6.1 In-house
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Contract Outsourcing
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Product Life Cycle

  • 7.1 Pre-clinical
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Phase I
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Phase II
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Phase III
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Phase IV
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Type

  • 8.1 Spontaneous Reporting
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Intensified ADR Reporting
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Targeted Spontaneous Reporting
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Cohort Event Monitoring
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 EHR Mining
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Process Flow

  • 9.1 Case Data Management
    • 9.1.1 Market Trends
    • 9.1.2 Major Types
      • 9.1.2.1 Case Logging
      • 9.1.2.2 Case Data Analysis
      • 9.1.2.3 Medical Reviewing and Reporting
    • 9.1.3 Market Forecast
  • 9.2 Signal Detection
    • 9.2.1 Market Trends
    • 9.2.2 Major Types
      • 9.2.2.1 Adverse Event Logging
      • 9.2.2.2 Adverse Event Analysis
      • 9.2.2.3 Adverse Event Review and Reporting
    • 9.2.3 Market Forecast
  • 9.3 Risk Management System
    • 9.3.1 Market Trends
    • 9.3.2 Major Types
      • 9.3.2.1 Risk Evaluation System
      • 9.3.2.2 Risk Mitigation System
    • 9.3.3 Market Forecast

10 Market Breakup by Therapeutic Area

  • 10.1 Oncology
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Neurology
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Cardiology
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Respiratory Systems
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast
  • 10.5 Others
    • 10.5.1 Market Trends
    • 10.5.2 Market Forecast

11 Market Breakup by End Use

  • 11.1 Pharmaceuticals Companies
    • 11.1.1 Market Trends
    • 11.1.2 Market Forecast
  • 11.2 Biotechnology Companies
    • 11.2.1 Market Trends
    • 11.2.2 Market Forecast
  • 11.3 Medical Device Companies
    • 11.3.1 Market Trends
    • 11.3.2 Market Forecast
  • 11.4 Others
    • 11.4.1 Market Trends
    • 11.4.2 Market Forecast

12 Market Breakup by Region

  • 12.1 North America
    • 12.1.1 United States
      • 12.1.1.1 Market Trends
      • 12.1.1.2 Market Forecast
    • 12.1.2 Canada
      • 12.1.2.1 Market Trends
      • 12.1.2.2 Market Forecast
  • 12.2 Asia-Pacific
    • 12.2.1 China
      • 12.2.1.1 Market Trends
      • 12.2.1.2 Market Forecast
    • 12.2.2 Japan
      • 12.2.2.1 Market Trends
      • 12.2.2.2 Market Forecast
    • 12.2.3 India
      • 12.2.3.1 Market Trends
      • 12.2.3.2 Market Forecast
    • 12.2.4 South Korea
      • 12.2.4.1 Market Trends
      • 12.2.4.2 Market Forecast
    • 12.2.5 Australia
      • 12.2.5.1 Market Trends
      • 12.2.5.2 Market Forecast
    • 12.2.6 Indonesia
      • 12.2.6.1 Market Trends
      • 12.2.6.2 Market Forecast
    • 12.2.7 Others
      • 12.2.7.1 Market Trends
      • 12.2.7.2 Market Forecast
  • 12.3 Europe
    • 12.3.1 Germany
      • 12.3.1.1 Market Trends
      • 12.3.1.2 Market Forecast
    • 12.3.2 France
      • 12.3.2.1 Market Trends
      • 12.3.2.2 Market Forecast
    • 12.3.3 United Kingdom
      • 12.3.3.1 Market Trends
      • 12.3.3.2 Market Forecast
    • 12.3.4 Italy
      • 12.3.4.1 Market Trends
      • 12.3.4.2 Market Forecast
    • 12.3.5 Spain
      • 12.3.5.1 Market Trends
      • 12.3.5.2 Market Forecast
    • 12.3.6 Russia
      • 12.3.6.1 Market Trends
      • 12.3.6.2 Market Forecast
    • 12.3.7 Others
      • 12.3.7.1 Market Trends
      • 12.3.7.2 Market Forecast
  • 12.4 Latin America
    • 12.4.1 Brazil
      • 12.4.1.1 Market Trends
      • 12.4.1.2 Market Forecast
    • 12.4.2 Mexico
      • 12.4.2.1 Market Trends
      • 12.4.2.2 Market Forecast
    • 12.4.3 Others
      • 12.4.3.1 Market Trends
      • 12.4.3.2 Market Forecast
  • 12.5 Middle East and Africa
    • 12.5.1 Market Trends
    • 12.5.2 Market Breakup by Country
    • 12.5.3 Market Forecast

13 SWOT Analysis

  • 13.1 Overview
  • 13.2 Strengths
  • 13.3 Weaknesses
  • 13.4 Opportunities
  • 13.5 Threats

14 Value Chain Analysis

15 Porters Five Forces Analysis

  • 15.1 Overview
  • 15.2 Bargaining Power of Buyers
  • 15.3 Bargaining Power of Suppliers
  • 15.4 Degree of Competition
  • 15.5 Threat of New Entrants
  • 15.6 Threat of Substitutes

16 Price Analysis

17 Competitive Landscape

  • 17.1 Market Structure
  • 17.2 Key Players
  • 17.3 Profiles of Key Players
    • 17.3.1 Accenture plc
      • 17.3.1.1 Company Overview
      • 17.3.1.2 Product Portfolio
      • 17.3.1.3 Financials
      • 17.3.1.4 SWOT Analysis
    • 17.3.2 ArisGlobal LLC
      • 17.3.2.1 Company Overview
      • 17.3.2.2 Product Portfolio
    • 17.3.3 BioClinica Inc. (Cinven Partners LLP)
      • 17.3.3.1 Company Overview
      • 17.3.3.2 Product Portfolio
      • 17.3.3.3 SWOT Analysis
    • 17.3.4 Capgemini
      • 17.3.4.1 Company Overview
      • 17.3.4.2 Product Portfolio
    • 17.3.5 Cognizant
      • 17.3.5.1 Company Overview
      • 17.3.5.2 Product Portfolio
      • 17.3.5.3 Financials
      • 17.3.5.4 SWOT Analysis
    • 17.3.6 International Business Machines Corporation
      • 17.3.6.1 Company Overview
      • 17.3.6.2 Product Portfolio
      • 17.3.6.3 Financials
      • 17.3.6.4 SWOT Analysis
    • 17.3.7 ICON plc.
      • 17.3.7.1 Company Overview
      • 17.3.7.2 Product Portfolio
      • 17.3.7.3 Financials
      • 17.3.7.4 SWOT Analysis
    • 17.3.8 IQVIA Inc.
      • 17.3.8.1 Company Overview
      • 17.3.8.2 Product Portfolio
      • 17.3.8.3 Financials
      • 17.3.8.4 SWOT Analysis
    • 17.3.9 ITClinical
      • 17.3.9.1 Company Overview
      • 17.3.9.2 Product Portfolio
    • 17.3.10 Parexel International Corporation
      • 17.3.10.1 Company Overview
      • 17.3.10.2 Product Portfolio
      • 17.3.10.3 SWOT Analysis
    • 17.3.11 Wipro Limited
      • 17.3.11.1 Company Overview
      • 17.3.11.2 Product Portfolio
      • 17.3.11.3 Financials
      • 17.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Pharmacovigilance Market: Major Drivers and Challenges
  • Figure 2: Global: Pharmacovigilance Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Pharmacovigilance Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Pharmacovigilance Market: Breakup by Service Provider (in %), 2023
  • Figure 5: Global: Pharmacovigilance Market: Breakup by Product Life Cycle (in %), 2023
  • Figure 6: Global: Pharmacovigilance Market: Breakup by Type (in %), 2023
  • Figure 7: Global: Pharmacovigilance Market: Breakup by Process Flow (in %), 2023
  • Figure 8: Global: Pharmacovigilance Market: Breakup by Therapeutic Area (in %), 2023
  • Figure 9: Global: Pharmacovigilance Market: Breakup by End Use (in %), 2023
  • Figure 10: Global: Pharmacovigilance Market: Breakup by Region (in %), 2023
  • Figure 11: Global: Pharmacovigilance (In-house) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Pharmacovigilance (In-house) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Pharmacovigilance (Contract Outsourcing) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Pharmacovigilance (Contract Outsourcing) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Pharmacovigilance (Pre-clinical) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Pharmacovigilance (Pre-clinical) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Pharmacovigilance (Phase I) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Pharmacovigilance (Phase I) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Pharmacovigilance (Phase II) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Pharmacovigilance (Phase II) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Pharmacovigilance (Phase III) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Pharmacovigilance (Phase III) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Pharmacovigilance (Phase IV) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Pharmacovigilance (Phase IV) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Pharmacovigilance (Spontaneous Reporting) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Pharmacovigilance (Spontaneous Reporting) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Pharmacovigilance (Intensified ADR Reporting) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Pharmacovigilance (Intensified ADR Reporting) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Pharmacovigilance (Targeted Spontaneous Reporting) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Pharmacovigilance (Targeted Spontaneous Reporting) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Pharmacovigilance (Cohort Event Monitoring) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Pharmacovigilance (Cohort Event Monitoring) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Pharmacovigilance (EHR Mining) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Pharmacovigilance (EHR Mining) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Pharmacovigilance (Case Data Management) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Pharmacovigilance (Case Data Management) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Pharmacovigilance (Signal Detection) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Pharmacovigilance (Signal Detection) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Global: Pharmacovigilance (Risk Management System) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Global: Pharmacovigilance (Risk Management System) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Global: Pharmacovigilance (Oncology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Global: Pharmacovigilance (Oncology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Global: Pharmacovigilance (Neurology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Global: Pharmacovigilance (Neurology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Global: Pharmacovigilance (Cardiology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Global: Pharmacovigilance (Cardiology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Global: Pharmacovigilance (Respiratory Systems) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Global: Pharmacovigilance (Respiratory Systems) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Global: Pharmacovigilance (Other Therapeutic Areas) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Global: Pharmacovigilance (Other Therapeutic Areas) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Global: Pharmacovigilance (Pharmaceuticals Companies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Global: Pharmacovigilance (Pharmaceuticals Companies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Global: Pharmacovigilance (Biotechnology Companies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Global: Pharmacovigilance (Biotechnology Companies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Global: Pharmacovigilance (Medical Device Companies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Global: Pharmacovigilance (Medical Device Companies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Global: Pharmacovigilance (Other End Uses) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Global: Pharmacovigilance (Other End Uses) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: North America: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: North America: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: United States: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: United States: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Canada: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Canada: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Asia-Pacific: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Asia-Pacific: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: China: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: China: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Japan: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Japan: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: India: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: India: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: South Korea: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: South Korea: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Australia: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Australia: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Indonesia: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Indonesia: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Others: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Others: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Europe: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Europe: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Germany: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Germany: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: France: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: France: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: United Kingdom: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 88: United Kingdom: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 89: Italy: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 90: Italy: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 91: Spain: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 92: Spain: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 93: Russia: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 94: Russia: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 95: Others: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 96: Others: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 97: Latin America: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 98: Latin America: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 99: Brazil: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 100: Brazil: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 101: Mexico: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 102: Mexico: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 103: Others: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 104: Others: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 105: Middle East and Africa: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 106: Middle East and Africa: Pharmacovigilance Market: Breakup by Country (in %), 2023
  • Figure 107: Middle East and Africa: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 108: Global: Pharmacovigilance Industry: SWOT Analysis
  • Figure 109: Global: Pharmacovigilance Industry: Value Chain Analysis
  • Figure 110: Global: Pharmacovigilance Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pharmacovigilance Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Pharmacovigilance Market Forecast: Breakup by Service Provider (in Million US$), 2024-2032
  • Table 3: Global: Pharmacovigilance Market Forecast: Breakup by Product Life Cycle (in Million US$), 2024-2032
  • Table 4: Global: Pharmacovigilance Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 5: Global: Pharmacovigilance Market Forecast: Breakup by Process Flow (in Million US$), 2024-2032
  • Table 6: Global: Pharmacovigilance Market Forecast: Breakup by Therapeutic Area (in Million US$), 2024-2032
  • Table 7: Global: Pharmacovigilance Market Forecast: Breakup by End Use (in Million US$), 2024-2032
  • Table 8: Global: Pharmacovigilance Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 9: Global: Pharmacovigilance Market: Competitive Structure
  • Table 10: Global: Pharmacovigilance Market: Key Players